Legal Issues

Pittsburgh company settles suit over hepatitis C drug

Published in Hepatitis Weekly, March 3rd, 2003

Generic drug maker Three Rivers Pharmaceuticals says it has settled a patent battle over a hepatitis C drug with Schering-Plough Corp.

As part of the settlement, Kenilworth, New Jersey-based Schering-Plough will license its U.S. patents for the antiviral drug ribavirin to Three Rivers for royalties on the generic version of the drug.

Three Rivers, based in suburban Pittsburgh, has been battling for 3 years to sell a generic version of ribavirin, which is used in combination with alpha interferon-2b to treat hepatitis C and generated $800 million in sales for Schering-Plough.

Three Rivers still needs approval from the U.S. Food and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-03-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry